ArticleCell death & disease2026
Probiotic interventions maintain intestinal barrier function and alleviate necrotizing enterocolitis by inhibiting ferroptosis in intestinal PMN-MDSCs.
Article in Cell death & disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Circulating polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) and gut probiotics are crucial for alleviating experimental necrotizing enterocolitis (NEC) in mice, yet the mechanisms linking intestinal PMN-MDSCs (iPMN-MDSCs) to specific microbiota remain unclear. Herein, we identified Lactobacillus (L.) reuteri and L. rhamnosus as two key strains significantly reduced under NEC conditions; their combined supplementation increased iPMN-MDSC abundance and olfactomedin 4 (OLFM4) expression, thereby improving intestinal epithelial cell (IEC) function and attenuating NEC. Olfm4 deficiency in neutrophils exacerbated NEC, disrupted intestinal barrier integrity, and induced microbial dysbiosis. Mechanistically, OLFM4 inhibited iPMN-MDSC ferroptosis by enhancing activating transcription factor 4 (ATF4) activity and upregulating its targets solute carrier family 7a member 11 (Slc7a11) and glutathione peroxidase 4 (Gpx4). Downregulation of Atf4 or Gpx4 recapitulated the phenotypic alterations observed in Olfm4-deficient mice, including aggravated NEC and impaired iPMN-MDSC function. Treatment with indole-3-aldehyde, an effector metabolite of probiotics, alleviated NEC by restoring the OLFM4-driven anti-ferroptosis axis in iPMN-MDSCs. In patients with NEC, reduced intestinal LOX1
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.